Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Ketogenic Diet Enhances the Cholesterol Accumulation in Liver and Augments the Severity of CCl 4 and TAA-Induced Liver Fibrosis in Mice.

Tytuł:
Ketogenic Diet Enhances the Cholesterol Accumulation in Liver and Augments the Severity of CCl 4 and TAA-Induced Liver Fibrosis in Mice.
Autorzy:
Liao YJ; School of Medical Laboratory Science and Biotechnology, College of Medical Science and Technology, Taipei Medical University, Taipei 110, Taiwan.
Wang YH; School of Medical Laboratory Science and Biotechnology, College of Medical Science and Technology, Taipei Medical University, Taipei 110, Taiwan.
Wu CY; School of Medical Laboratory Science and Biotechnology, College of Medical Science and Technology, Taipei Medical University, Taipei 110, Taiwan.
Hsu FY; School of Medical Laboratory Science and Biotechnology, College of Medical Science and Technology, Taipei Medical University, Taipei 110, Taiwan.
Chien CY; School of Medical Laboratory Science and Biotechnology, College of Medical Science and Technology, Taipei Medical University, Taipei 110, Taiwan.
Lee YC; School of Medical Laboratory Science and Biotechnology, College of Medical Science and Technology, Taipei Medical University, Taipei 110, Taiwan.
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2021 Mar 13; Vol. 22 (6). Date of Electronic Publication: 2021 Mar 13.
Typ publikacji:
Journal Article
Język:
English
Imprint Name(s):
Original Publication: Basel, Switzerland : MDPI, [2000-
MeSH Terms:
3-Hydroxybutyric Acid/*pharmacology
Acetoacetates/*pharmacology
Cholesterol/*biosynthesis
Diet, Ketogenic/*adverse effects
Liver/*drug effects
Liver Cirrhosis/*metabolism
3-Hydroxybutyric Acid/biosynthesis ; Acetoacetates/metabolism ; Actins/genetics ; Actins/metabolism ; Animals ; Becaplermin/pharmacology ; Carbon Tetrachloride/administration & dosage ; Catalase/genetics ; Catalase/metabolism ; Cell Proliferation/drug effects ; Cholesterol/blood ; Collagen Type I/genetics ; Collagen Type I/metabolism ; Cytochrome P-450 CYP1A2/genetics ; Cytochrome P-450 CYP1A2/metabolism ; Desmin/genetics ; Desmin/metabolism ; Disease Progression ; Gene Expression Regulation/drug effects ; Hepatic Stellate Cells/cytology ; Hepatic Stellate Cells/drug effects ; Hepatic Stellate Cells/metabolism ; Liver/metabolism ; Liver/pathology ; Liver Cirrhosis/chemically induced ; Liver Cirrhosis/genetics ; Liver Cirrhosis/pathology ; Male ; Mice ; Mice, Inbred C57BL ; Primary Cell Culture ; Severity of Illness Index ; Superoxide Dismutase/genetics ; Superoxide Dismutase/metabolism ; Superoxide Dismutase-1/genetics ; Superoxide Dismutase-1/metabolism ; Thioacetamide/administration & dosage ; Transforming Growth Factor beta/biosynthesis ; Transforming Growth Factor beta/pharmacology
References:
Exp Clin Endocrinol Diabetes. 2015 Feb;123(2):88-94. (PMID: 25654672)
Science. 2013 Jan 11;339(6116):211-4. (PMID: 23223453)
Z Gastroenterol. 2006 Jan;44(1):57-66. (PMID: 16397841)
Physiol Rev. 2008 Jan;88(1):125-72. (PMID: 18195085)
Cell Metab. 2019 Feb 5;29(2):383-398.e7. (PMID: 30449686)
Nutrition. 2014 Jul-Aug;30(7-8):814-21. (PMID: 24984998)
Nat Rev Gastroenterol Hepatol. 2017 Jul;14(7):397-411. (PMID: 28487545)
Eur J Endocrinol. 2012 Mar;166(3):487-92. (PMID: 22190000)
J Hepatol. 2018 Sep;69(3):687-696. (PMID: 29705237)
Cancers (Basel). 2019 Nov 26;11(12):. (PMID: 31779269)
J Clin Invest. 2015 Nov 03;125(12):4601-11. (PMID: 26529252)
Nutrients. 2019 Sep 26;11(10):. (PMID: 31561520)
Nutrition. 2019 Apr;60:118-121. (PMID: 30554068)
Lancet. 2008 Mar 8;371(9615):838-51. (PMID: 18328931)
Compr Physiol. 2013 Oct;3(4):1473-92. (PMID: 24265236)
Gastroenterology. 2010 Aug;139(2):456-63. (PMID: 20451522)
Endocrinology. 2007 Feb;148(2):774-81. (PMID: 17068132)
Br J Nutr. 2013 Oct;110(7):1178-87. (PMID: 23651522)
Eur J Clin Nutr. 2013 Aug;67(8):789-96. (PMID: 23801097)
Am J Clin Nutr. 2011 Apr;93(4):901S-5. (PMID: 21346090)
Mol Metab. 2013 Jul 08;2(3):306-13. (PMID: 24049742)
Nutr Metab (Lond). 2012 Jul 28;9(1):69. (PMID: 22838969)
Lancet. 2015 Dec 5;386(10010):2287-323. (PMID: 26364544)
Int J Environ Res Public Health. 2014 Feb 19;11(2):2092-107. (PMID: 24557522)
Clin Liver Dis. 2007 Feb;11(1):1-16, vii. (PMID: 17544968)
Nutrients. 2020 Jun 29;12(7):. (PMID: 32610627)
Am J Physiol Endocrinol Metab. 2014 Mar 1;306(5):E552-8. (PMID: 24398402)
Neurobiol Aging. 2016 Dec;48:34-47. (PMID: 27639119)
Mediators Inflamm. 2014;2014:983401. (PMID: 24803746)
Adv Drug Deliv Rev. 2017 Nov 1;121:27-42. (PMID: 28506744)
Mol Med Rep. 2017 Dec;16(6):7879-7889. (PMID: 28983598)
Cancers (Basel). 2020 Jul 04;12(7):. (PMID: 32635582)
J Clin Endocrinol Metab. 2009 Sep;94(9):3594-601. (PMID: 19531592)
Frontline Gastroenterol. 2014 Oct;5(4):277-286. (PMID: 25285192)
Cell Metab. 2008 Aug;8(2):169-74. (PMID: 18680716)
Endocr Rev. 2017 Oct 1;38(5):468-488. (PMID: 28938407)
J Hepatol. 2015 Mar;62(3):599-606. (PMID: 25450719)
Neurosci Lett. 2009 Mar 27;453(1):49-53. (PMID: 19429014)
Cell Metab. 2007 Jun;5(6):426-37. (PMID: 17550778)
Cell Metab. 2017 Feb 7;25(2):262-284. (PMID: 28178565)
Int J Mol Sci. 2016 Jul 13;17(7):. (PMID: 27420058)
Aliment Pharmacol Ther. 2011 Aug;34(3):274-85. (PMID: 21623852)
Nutrition. 2006 Nov-Dec;22(11-12):1185-91. (PMID: 17095404)
Am J Clin Nutr. 2011 May;93(5):1048-52. (PMID: 21367948)
Epilepsy Behav. 2016 Feb;55:165-9. (PMID: 26785223)
Am J Physiol Endocrinol Metab. 2011 Jan;300(1):E65-76. (PMID: 20943751)
Nutrients. 2019 Oct 01;11(10):. (PMID: 31581549)
Cancer Metab. 2014 Sep 01;2:18. (PMID: 25228990)
N Engl J Med. 2015 Jul 2;373(1):96. (PMID: 26132959)
Curr Opin Clin Nutr Metab Care. 2012 Jul;15(4):374-80. (PMID: 22617564)
Trends Endocrinol Metab. 2012 Jul;23(7):351-63. (PMID: 22704720)
Ann Intern Med. 2010 Aug 3;153(3):147-57. (PMID: 20679559)
Grant Information:
MOST 109-2628-B-038-020 Ministry of Science and Technology of the Republic of China
Contributed Indexing:
Keywords: acetoacetate; hepatic stellate cells; high-fat ketogenic diet; liver fibrosis; β-hydroxybutyrate
Substance Nomenclature:
0 (Acetoacetates)
0 (Actins)
0 (Col1a2 protein, mouse)
0 (Collagen Type I)
0 (Desmin)
0 (Transforming Growth Factor beta)
0 (alpha-smooth muscle actin, mouse)
075T165X8M (Thioacetamide)
1B56C968OA (Becaplermin)
4ZI204Y1MC (acetoacetic acid)
97C5T2UQ7J (Cholesterol)
CL2T97X0V0 (Carbon Tetrachloride)
EC 1.11.1.6 (Catalase)
EC 1.14.14.1 (Cytochrome P-450 CYP1A2)
EC 1.14.14.1 (cytochrome P-450 1A2, mouse)
EC 1.15.1.1 (Sod1 protein, mouse)
EC 1.15.1.1 (Superoxide Dismutase)
EC 1.15.1.1 (Superoxide Dismutase-1)
EC 1.15.1.1 (superoxide dismutase 2)
TZP1275679 (3-Hydroxybutyric Acid)
Entry Date(s):
Date Created: 20210403 Date Completed: 20210423 Latest Revision: 20210423
Update Code:
20240104
PubMed Central ID:
PMC7998170
DOI:
10.3390/ijms22062934
PMID:
33805788
Czasopismo naukowe
Persistent chronic liver diseases increase the scar formation and extracellular matrix accumulation that further progress to liver fibrosis and cirrhosis. Nevertheless, there is no antifibrotic therapy to date. The ketogenic diet is composed of high fat, moderate to low-protein, and very low carbohydrate content. It is mainly used in epilepsy and Alzheimer's disease. However, the effects of the ketogenic diet on liver fibrosis remains unknown. Through ketogenic diet consumption, β-hydroxybutyrate (bHB) and acetoacetate (AcAc) are two ketone bodies that are mainly produced in the liver. It is reported that bHB and AcAc treatment decreases cancer cell proliferation and promotes apoptosis. However, the influence of bHB and AcAc in hepatic stellate cell (HSC) activation and liver fibrosis are still unclear. Therefore, this study aimed to investigate the effect of the ketogenic diet and ketone bodies in affecting liver fibrosis progression. Our study revealed that feeding a high-fat ketogenic diet increased cholesterol accumulation in the liver, which further enhanced the carbon tetrachloride (CCl 4 )- and thioacetamide (TAA)-induced liver fibrosis. In addition, more severe liver inflammation and the loss of hepatic antioxidant and detoxification ability were also found in ketogenic diet-fed fibrotic mouse groups. However, the treatment with ketone bodies (bHB and AcAc) did not suppress transforming growth factor-β (TGF-β)-induced HSC activation, platelet-derived growth factor (PDGF)-BB-triggered proliferation, and the severity of CCl 4 -induced liver fibrosis in mice. In conclusion, our study demonstrated that feeding a high-fat ketogenic diet may trigger severe steatohepatitis and thereby promote liver fibrosis progression. Since a different ketogenic diet composition may exert different metabolic effects, more evidence is necessary to clarify the effects of a ketogenic diet on disease treatment.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies